Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take on multiple sclerosis and more

NCT ID NCT07304154

First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 18 times

Summary

This early-phase study tests a new treatment called KITE-363, which uses a patient's own modified immune cells to target and attack harmful immune cells causing nerve damage. It is for people with relapsed or hard-to-treat autoimmune neurologic diseases like multiple sclerosis, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The main goals are to check safety, find the right dose, and see if it can improve symptoms.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Concord Repatriation General Hospital

    RECRUITING

    Sydney, New South Wales, 2139, Australia

  • Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

  • LDS Hospital - Intermountain Health

    RECRUITING

    Salt Lake City, Utah, 84143, United States

Conditions

Explore the condition pages connected to this study.